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A B S T R A C T   
Background: Previous studies describe a large variation in the proportion of patients undergoing treatment with 
curative intent for esophageal (EC) and gastric cancer (GC). Since centralization of surgical care was initiated and 
more awareness regarding hospital practice variation was potentially present, we hypothesized that hospital 
practice variation for potentially curable EC and GC patients changed over time. 
Methods: Patients with potentially curable EC (n = 10,115) or GC (n = 3988) diagnosed between 2012–2017 
were selected from the Netherlands Cancer Registry. Multilevel multivariable logistic regression was used to 
analyze the differences in the probability of treatment with curative intent between hospitals of diagnosis over 
time, comparing 2012− 2014 with 2015− 2017. Relative survival (RS) between hospitals with different proba-
bilities of treatment with curative intent were compared. 
Results: The range of proportions of patients undergoing treatment with curative intent per hospital of diagnosis 
for EC was 45–95 % in 2012− 2014 and 54–89 % in 2015− 2017, and for GC 52–100 % and 45–100 %. The 
adjusted variation declined for EC with Odds Ratios ranging from 0.50 to 1.72 between centers in the first period 
to 0.70–1.44 in the second period (p < 0.001) and did not change for GC (Odds Ratios ranging from 0.78 to 1.23 
to 0.82–1.23, (p = 1.00)). A higher probability of treatment with curative intent was associated with a better 
survival for both malignancies. 
Conclusion: Although substantial variation between hospitals of diagnosis in the probability in receiving treat-
ment with curative intent still exists for both malignancies, it has decreased for EC. A low probability of receiving 
curative treatment remained associated with worse survival.   
1. Introduction 
Geographical variation in cancer care has been observed between 
and within countries. [1–6] Variation in receiving treatment may occur 
at any point along the cancer care continuum attributing to potentially 
avoidable disparities in patient outcomes [3,4]. Earlier studies have 
shown that the probability of undergoing treatment with curative intent 
according to the hospital of diagnosis varied significantly for esophageal 
(EC) and gastric cancer (GC) between hospitals in the Netherlands in the 
period 2005–2013 [3,4,7]. Furthermore, in hospitals in which the 
probability of receiving treatment with curative intent was low, survival 
was also lower [3,4]. Regional variation in the use of (non-)surgical 
oncologic treatment modalities has also been observed internationally 
[2,5,8,9]. 
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The cornerstone of curative treatment for patients with these ma-
lignancies is surgery with or without (neo)adjuvant chemo(radiation) 
therapy. [10,11] Other treatment options with curative intent include 
endoscopic resection for early stage disease. For patients with locally 
unresectable EC or with EC who are too frail to undergo surgery, 
definitive chemoradiotherapy is an alternative [12,13]. 
As EC and GC surgery is associated with a high morbidity and mor-
tality [14], surgery for these malignancies is centralized in the 
Netherlands [15,16]. Centralization of esophageal surgery was initiated 
in 2006 by mandating an annual volume of at least 10 esophagectomies 
per hospital. Since 2011 this increased to 20 esophagectomies and since 
2013 a minimum of 20 gastrectomies per hospital were mandated. 
However, the diagnostic process, including the decision on operability 
or curability is mainly made in non-expert centers and consultation with 
and referral to an expert center might not always follow. In 2014 results 
were published on the regional variation in the Southeast Netherlands. 
[7] Simultaneously, the Dutch Comprehensive Cancer Organization 
facilitated regional meetings showing regional variation based on data 
of the Netherlands Cancer Registry (NCR). As a result of these de-
velopments, regional clinical pathways and tumor specific multidisci-
plinary team meetings (MDTM) were setup in almost all Dutch regions. 
Previous studies on this topic did not compare time periods before and 
after centralization [3,4]. Moreover, they do not describe the period 
after the publication of studies investigating hospital practice variation. 
We hypothesized that due to created awareness regarding hospital 
practice variation, variation would change over time. We aimed, to 
assess whether variation between hospitals in the probability of under-
going treatment with curative intent in patients with potentially curable 
EC or GC changed over time and to assess the effect of variation on 
survival. 
2. Methods 
In this study data of the NCR, a nationwide population-based cancer 
registry comprising all patients with cancer in the Netherlands, was 
used. The NCR is primarily based on the notification of all newly diag-
nosed malignancies by the pathological national automated archive. 
Additionally, non-pathologically verified cases are identified through 
the national registry of hospital care and discharge. Trained data man-
agers of the NCR routinely extract information on patient, tumor and 
treatment characteristics from medical records. Information on vital 
status is obtained through annual linkage with the Municipal Adminis-
trative Database, in which all deceased and emigrated persons in the 
Netherlands are registered, which is up to date until January 1st 2020. 
All patients newly diagnosed with potentially curable EC or GC 
(cT1− 4A,X, any cN, cM0) in 2012–2017 were included in this study. 
Gastro-esophageal junction (GEJ) and cardia carcinomas were included 
in the EC-group. Tumor location and morphology were coded according 
to the third edition of the International Classification of Diseases for 
Oncology. [17] For EC tumor location was categorized as proximal 
(C150/C153), mid (C154), distal (C155), GEJ/Cardia (C160), unknow-
n/overlapping (C158/C159). The following categories were used for GC: 
proximal/middle (fundus/corpus/lesser- and greater curvature) 
(C16.1/C16.2/C16.5/C16.6), pyloric/antrum (C16.3/C16.4), and 
unknown/overlapping (C16.8/C16.9). 
Tumors were staged using the International Union Against Cancer 
TNM classification. The seventh edition was used for the 2012–2016 and 
the eighth for 2017. [18,19] There were no changes in the T, N and M 
category definitions comparing the 7th to 8th edition of the TNM. 
However, the definition on when to use esophageal or gastric TNM 
staging did change, and as a result, a tumor of which the epicenter was 
located within 2− 5 cm from the GEJ was staged as EC in TNM-7 and as 
GC in TNM-8. In this study no corrections for the TNM-stages were 
applied, however GEJ tumors were all classified as EC. For 2015− 2017, 
information on comorbidity (modified Charlson Comorbidity Index) and 
ECOG performance status (ECOG) was available. 
No ethics approval was required according to the Central Committee 
on Research involving Human Subjects. 
2.1. Treatment with curative intent 
Treatment with curative intent was defined as the initiation of 
treatment with the aim of cure, which did not always imply that the 
patient ultimately would undergo the full treatment plan. This included 
the initiation of neoadjuvant treatment, surgery (with/without resec-
tion) with/without (neo)adjuvant chemo(radiation)therapy, endoscopic 
resection (cT1N0M0) and definitive chemoradiation (for EC). In some 
patients surgery with the aim of cure was initiated and the decision not 
to pursue resection, due to too severe disease, was taken during explo-
ration (surgery without resection). 
2.2. Hospital of diagnosis 
Hospital of diagnosis was defined as the hospital in which the his-
tological diagnosis was confirmed. Patients were excluded if the diag-
nosis was determined abroad (n = 7). Hospitals were excluded if <10 
patients were diagnosed in a three-year time period (N = 2, N = 2 for EC, 
N = 8, N = 12 for GC in 2012− 2014 and 2015− 2017, respectively) 
(Appendix A). For EC 94 hospitals of diagnosis were included in 
2012− 2014 and 80 in 2015− 2017. For GC 87 hospitals of diagnosis 
were included in 2012− 2014 and 69 in 2015− 2017. 
2.3. Outcomes and analysis 
The proportion of potentially curable EC or GC patients treated with 
curative intent was calculated per hospital of diagnosis. Differences in 
baseline patient characteristics between the two time periods were 
analyzed with the chi-square test. The probability of treatment with 
curative intent was defined as the proportion of patients diagnosed in a 
hospital, who underwent treatment with the aim of cure. Multivariable 
multilevel logistic regression models with random intercepts were con-
structed to analyze the hierarchically structured data. Undergoing 
treatment with curative intent or not, was used as dependent variable. 
Sex, age, histology, cT and cN classification were added to adjust for case 
mix differences. Missing data were coded as unknown and included in 
multivariable analyses. Results were expressed in odds ratios (ORs) with 
95 % confidence intervals (95 %CI). For each hospital of diagnosis, the 
OR with 95 %CI for treatment with curative intent was calculated. To 
assess the difference in hospital variation between the two time periods 
(2012− 2014 versus 2015− 2017), we compared a model with only a 
random intercept per hospital to a model with a random slope for period 
per hospital. Both models were adjusted for case mix differences (i.e., 
sex, age, histology, cT and cN). We tested the difference in –2log like-
lihood between these models with a Chi-square test. A subgroup analysis 
was conducted for patients diagnosed in 2015− 2017 for whom data on 
ECOG and comorbidity was available. In this model additional adjust-
ments for comorbidities and ECOG were made, to assess whether these 
variables explain the variation between hospitals of diagnosis. 
Relative survival (RS) was defined as the ratio of overall survival for 
cancer patients to the expected survival based on the Dutch population 
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with the same age, sex and calendar year as patients with these malig-
nancies. RS analyses with 95 % CI were calculated from date of diagnosis 
and according to the Pohar Perme method. [20] To assess the effect of 
the probability of undergoing treatment with curative intent on RS, we 
divided the hospitals in three groups based on tertiles of the adjusted 
ORs on the probability of undergoing treatment with curative intent. 
Since the groups were based on the tertiles of the multivariable model, 
no further adjustments for the survival analyses were necessary. Dif-
ference in RS between these groups was calculated using a two-sample 
proportion test. Relative excess risk of death (RER) was calculated for 
EC and GC, respectively. RS was calculated for all (EC n = 16,427 and 
GC n = 7124), potentially curable and palliative patients, in both time 
periods to provide a baseline description of RS in the Netherlands. For all 
analyses a p-value<0.05 was considered statistically significant. 
Statistical analyses were performed using SAS® version 9.4 (SAS 
Institute, Cary, North Carolina, USA). RS and the RER were analyzed 
using STATA/SE (version 14.1; STATA CORP., College Station, Texas, 
USA). 
3. Results 
In total, 10,115 patients with EC and 3988 patients with GC were 
selected. In 2012− 2014, 4796 (62 %) EC patients were according to the 
aforementioned definition potentially curable and in 2015− 2017 this 
Table 1 
Patient characteristics esophageal cancer for the period 2012-2014 and 2015-2017.   
Total 2012− 2014 2015− 2017   
N % N % N % p-value 
All included patients 10115 100 % 4796 100 % 5319 100 %  
Sex       0.043 
Female 2742 27 % 1255 26% 1487 28 %  
Male 7373 73 % 3541 74% 3832 72 %  
Age       <.001 
< 60 1769 17 % 905 19 % 864 16%  
60 to 74 5057 50 % 2327 49% 2730 51%  
75 and higher 3289 33 % 1564 33 % 1725 32%  
Histology       0.445 
Adenocarcinoma 2681 27 % 1299 27 % 1382 26%  
Squamous cell carcinoma 7143 71% 3362 70% 3781 71%  
Other 291 3% 135 3% 156 3%  
cT Classification    <.0001 
cT1 269 3% 131 3% 138 3%  
cT1A 183 2% 116 2% 67 1%  
cT1B 156 2% 72 2% 84 2%  
cT2 2773 27 % 1213 25 % 1560 29 %  
cT3 4641 46 % 2087 44% 2554 48 %  
cT4A 207 2% 124 3% 83 2%  
cT4B^ 24 0% 18 <1% 6 <1%  
cTX 1862 18% 1035 22% 827 16%  
cN Classification       <.0001 
cN0 4002 40 % 1812 38 % 2190 41 %  
cN1 3178 31% 1492 31% 1686 32%  
cN2 1611 16% 778 16% 833 16%  
cN3 268 3% 131 3% 137 3%  
cNX 1056 10 % 583 12 % 473 9%  
Tumor location    0.019 
Proximal 518 5% 261 5% 257 5%  
Middle 1395 14% 636 13 % 759 14%  
Distal 6259 62 % 2934 61 % 3325 63 %  
Overlapping/unknown 464 5% 213 4% 251 5%  
GEJ 1479 15 % 752 16% 727 14%  
Comorbidities     
No comorbidities  1526 29 %  
1 Comorbidity  1537 29 %  
>2 Comorbidities  1852 35 %  
Unknown  404 8%  
Patients clinical condition        
ECOG 0     1683 32%  
ECOG 1     1535 29 %  
ECOG 2     418 8%  
ECOG 3 and 4     166 3%  
Unknown  1517 28 %  
Type of treatment received       <.001 
Surgical resection 4858 48 % 2272 47 % 2586 49%  
Endoscopic resection 338 3% 163 3% 175 3%  
Only chemoradiation* 1938 19 % 866 18% 1072 20 %  
Other or no treatment 2981 29 % 1495 31% 1486 28 %  
Treatment with curative intent       <0.001 
No 2981 29 % 1495 31% 1486 28 %  
Yes 7134 71% 3301 69 % 3833 72 %  
x2 was used to calculate statistical differences between both periods in all analyses presented in this table. 
Column percentage, *For the period 2012− 2014 no differentiation between definitive chemoradiation and neoadjuvant chemoradiation not followed by resection 
could be made, ̂  Prior to surgery (without resection) the cT stage was below cT4b. During surgery the team decided to refrain from resection due to the extensiveness of 
the tumor and staged the tumor as cT4b. 
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was 5319 (62 %, p = 0.80, Appendix B). For GC, 2218 patients (60 %) in 
2012− 2014 and 1770 patients (56 %) in 2015− 2017, were potentially 
curable, which decreased over time (p < 0.001, Appendix B). 
3.1. Characteristics 
As shown in Table 1, most patients with EC in 2012–2017 were be-
tween 60–74 years old (50 %), followed by patients that were ≥75 years 
(33 %). A cT3 (46 %) and cN+ (50 %) tumor stage was observed in most 
patients. The percentage of EC patients in which treatment with curative 
intent was initiated increased from 69 % in 2012− 2014 to 72 % in 
2015− 2017 (p < 0.001). 
Most GC patients were ≥75 years (48 %), followed by 60–74 years 
(37 %, Table 2). A cT2 (33 %) and a cN0 (56 %) tumor stage was seen in 
most of the patients. Treatment with curative intent was initiated in 73 
%, which was the same in both periods (p = 0.111). 
3.2. Hospital variation 
The proportion of patients with EC that was treated with curative 
intent showed variation between hospitals in both periods (45–95 % in 
2012− 2014 vs. 54–89 % in 2015− 2017). For GC the variation was 
52–100 % and 45–100 %, respectively. 
Adjusted ORs (Fig. 1) for undergoing treatment with curative intent 
varied from 0.50 to 1.72 between hospitals in 2012− 2014 and from 0.70 
to 1.44 in 2015− 2017 for EC. The total variation between the hospitals 
decreased significantly over time (p < 0.01). Over time, decision mak-
ing behavior of hospitals changed: 46 % of the hospitals remained in the 
Table 2 
Patient characteristics gastric cancer for the period 2012-2014 and 2015-2017.   
Total  2012− 2014 2015− 2017   
N % N % N % p-value 
All included patients 3988 100 % 2218 100 % 1770 100 %  
Sex       0.519 
Female 1571 39 % 864 39 % 707 40 %  
Male 2417 61 % 1354 61 % 1063 60 %  
Age       0.026 
< 60 599 15 % 347 16% 252 14%  
60 to 74 1481 37 % 852 38 % 629 35 %  
75 and higher 1908 48 % 1019 46 % 881 50 %  
Histology       0.918 
Adenocarcinoma 3881 97% 2159 97% 1722 97%  
Other 107 3% 59 3% 48 3%  
cT Classification    <.0001 
cT1 114 3% 71 3% 44 2%  
cT1A 61 2% 43 2% 19 1%  
cT1B 42 1% 19 <1% 23 1%  
cT2 1307 33 % 662 30 % 644 36 %  
cT3 744 19 % 355 16% 388 22%  
cT4A 139 3% 60 3% 79 4%  
cT4B^ 118 3% 81 4% 37 2%  
cTX 1463 37 % 927 42 % 536 30 %  
cN Classification    <.001 
cN0 2250 56 % 1250 56 % 1000 57%  
cN1 700 18% 349 16% 351 20 %  
cN2 377 9% 212 10 % 165 9%  
cN3A 33 1% 15 <1% 18 1%  
cN3B 6 0.15 % 2 <1% 4 <1%  
cN X 622 16% 390 18% 232 13 %  
Tumor location    <.001 
Proximal/Middle 1254 31% 708 32% 549 31%  
Pyloric and antrum 1672 42 % 882 40 % 790 45 %  
Overlapping/unknown 1059 27 % 628 28 % 431 24%  
Comorbidities     
No comorbidities  449 25 %  
1 Comorbidity  484 27 %  
>2 Comorbidities  686 39 %  
Unknown  150 8%  
Patients clinical condition    
ECOG 0     420 24%  
ECOG 1     436 25 %  
ECOG 2     125 7%  
ECOG 3 and 4     57 3%  
Unknown     732 41 %  
Type of treatment received       0.315 
Surgical resection 2711 40 % 1532 69 % 1179 67%  
Endoscopic resection 43 30 % 21 <1% 22 1%  
Only neoadjuvant chemoradiotherapy 155 3% 87 4% 68 4%  
Other or no treatment 1079 27 % 578 26% 501 28 %  
Curative treatment received   0.111 
No 1079 27 % 578 26% 501 28 %  
Yes 2909 73 % 1640 74% 1269 72 %  
x2 was used to calculate statistical differences between both periods in all analyses presented in this table. 
Column percentage. 
^Prior to surgery (without resection) the cT stage was below cT4b. During surgerythe team decided to refrain from resection due to the extensiveness of the tumor and 
staged the tumor as cT4b. 
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same probability group, 25 % were grouped in a higher probability 
group and 29 % in a lower probability group (Appendix C). 
For GC, the adjusted ORs remained stable (p = 1.00) and ranged from 
0.78 to 1.23 in 2012− 2014 and from 0.82 to 1.22 in 2015− 2017 
(Fig. 1). Over time decision making behavior of hospitals changed: 47 % 
of the hospitals remained in the same probability group, 25 % were 
grouped in a higher probability group and 28 % in a lower probability 
group (Appendix C). 
Sensitivity analysis for the period 2015− 2017 showed after adjust-
ment for comorbidities and ECOG, that variation in the probability of 
undergoing treatment with curative intent between hospitals increased 
or remained stable. For EC, the OR ranged from 0.64 to 1.54 and for GC 
the OR ranged from 0.82 to 1.18, implying that variation in treatment 
with curative intent between hospital of diagnosis in both malignancies 
could not be explained by comorbidities or ECOG. 
3.3. Survival 
Three-year RS for all patients diagnosed with EC increased signifi-
cantly over time (25 % – 27 %, p = 0.027) and increased non significantly 
in potentially curable and palliative patients. For GC no significant differ-
ences in RS were observed (23 % - 23 %, p = 0.278) (Appendix D). 
For EC (2015− 2017), 3-year RS was 35 % (95 % CI 33–37), 38 % (95 
% CI 36–40), 41 % (95 % CI 38–43) in the low, medium and high 
probability of undergoing treatment with curative intent group respec-
tively. Similar results were observed for 2012− 2014 (Table 3.). Patients 
diagnosed in a hospital with a high probability of undergoing treatment 
for EC with curative intent had a higher RS compared to those in hos-
pitals with a low probability (p < 0.0001) in both periods. The RER also 
was lower when diagnosed in a hospital with a high versus low 
probability in 2012− 2014 (0.84, 95 % CI, 0.77− 0.91, p < 0.0001) and 
in 2015− 2017 (0.84, 95 % CI, 0.77− 0.91, p < 0.0001) (Table 4). 
For GC (2015− 2017), 3-year RS was 34 % (95 % CI 30–38), 36 % (95 
% CI 31–40), and 39 % (95 % CI 36–43) in the low, medium and high 
probability of undergoing treatment with curative intent group respec-
tively (p < 0.037). Similar results were observed for 2012− 2014 
(Table 3). Patients diagnosed in a hospital with a high probability of 
undergoing treatment with curative intent for GC had a higher RS in 
both periods compared to those with a low probability. The RER also 
was lower when diagnosed in a hospital with a high probability in 
2012− 2014 (0.81 (95 %CI, 0.72− 0.91, p < 0.0001)) and in 2015− 2017 
(0.86 (95 % CI, 0.75− 0.99, p < 0.037)) (Table4). 
4. Discussion 
In this study, variation in the probability of receiving treatment with 
curative intent for EC and GC according to hospital of diagnosis was 
assessed for two successive periods in the Netherlands. Significantly 
more patients with EC underwent treatment with curative intent in the 
second period (69 % – 72 %, p < 0.001), meaning more patients could 
undergo a potentially curative treatment. In our study, variation be-
tween hospitals of diagnosis decreased over time for EC (p < 0.01) but 
remained the same for GC (p = 1.00). Moreover, comparing the two 
times periods, overall RS increased for all EC patients and remained 
stable for all GC patients. Importantly, in both malignancies being 
diagnosed in a hospital with a high probability of being treated with 
curative intent was associated with an improved survival. 
The cause of practice variation remains to be elucidated and is likely 
due to a variety of factors. Variation in cancer care typically occurs when 
accepted standards of care do not exist for a disease or when resources 
Fig. 1. adjusted odds ratios on the probability of receiving treatment with curative intent according to the hospital of diagnosis for esophageal and gastric cancer on 
a logarithmic scale. Adjusted for: age, sex, cT and cN stage and histology. Esophageal cancer (EC), Gastric cancer (GC). 
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are limited or unavailable. [1,21,22] The latter was not the case in the 
Netherlands and accepted guidelines were universally available [7,10, 
11]. Guidelines may be interpreted differently especially when evidence 
is equivocal or lacking, which may lead to variation [22–26]. Further-
more, variation might be influenced by hospital based factors such as 
hospital type, physician’s preferences [26,27] and experience [28], and 
the organization of MDTMs [29,30]. Nevertheless, variation slightly 
decreased in EC, which might partially be explained by the imple-
mentation of regional clinical pathways, regional MDTMs or changes in 
attitude towards surgery [31]. However, these are mere speculations 
and robust evidence regarding factors explaining hospital variation is 
lacking and further research is needed to elucidate these factors. 
Moreover, a national process improvement program, with continuous 
monitoring effectiveness and quality of diagnostics and referral with 
subsequent improving actions, should be undertaken to reduce vari-
ability and achieve changes in treatment [32]. 
Comorbidities and ECOG are important patient characteristics 
influencing treatment decision-making. [33] Based on the described 
subgroup analyses, difference in comorbidities and ECOG could not 
explain the observed variation in the latter period. Hence, other factors 
are more likely related to the observed variation. Possible associated 
factors could be the different organizational structure of the hospitals 
regarding clinical pathways, MDTM, physician’s preference and expe-
rience and culture within a hospital and treatment team [34–36]. Phy-
sicians may well have different perception of the benefits and harms 
[35] and expected quality of life after treatment, which in turn will 
affect the decisional processes. Nevertheless, these perceptions are hard 
to quantify and are certainly not registered in patient’s medical files. 
Moreover, it is unlikely that the variation according to hospital of 
diagnosis is influenced by patients’ preferences. Because in the 
Netherlands the general practitioner generally refers the patient to the 
hospital which is close to the patient’s home address. For a further un-
derstanding and elucidation of reasons explaining variation, a more 
qualitative research approach is needed, which is currently undertaken 
by our group. 
Patient specific parameters, such as a patient’s preference to undergo 
surgery or another treatment, patient’s social economic status (SES) and 
the influence of a patient’s relatives, will also play an important role. [7, 
37] Lux et al. concluded in breast cancer patients that satisfaction with 
treatment benefits differed to some extent between patients and this was 
influenced by educational level and previous experiences with other 
types of therapy [35]. In the Netherlands SES and educational level 
differ per region [38] and this might at least partly affects the observed 
variation. Moreover, one third of the group of breast cancer patients 
delegate the responsibility of the treatment decision to their physician 
[39]. This implies that, the probability of receiving treatment with 
curative intent is also determined by preferences of the treating physi-
cian. Hence, the ultimate treatment decision is influenced by the shared 
decisional processes of physician’s and patient’s preferences. In this 
study, solely the conclusion of this decision-making process could be 
assessed. 
While variation in undergoing treatment with curative intent for EC 
decreased, no major adjustments in the Dutch guidelines were made 
[24]. In this study an unchanged variation in the probability of receiving 
treatment with curative intent in GC was observed. A Dutch study found 
in the period in which centralization of esophagectomies was initiated, 
hospital surgery volume was associated with the probability of under-
going treatment with curative intent. These associations were only 
Table 3 
Probability of undergoing treatment with curative intent and relative survival across calendar periods in patients with EC or GC, stratified by probability of undergoing 
treatment with curative intent per initial hospital of diagnosis in 2012-2017.   
Esophageal cancer  
Probability of undergoing treatment with curative intent in % 1 yr RS in % (95 % CI) 3 yr RS in % (95 % CI) 5 yr RS in % (95 % CI) P 
2012− 2014 
Low 45–66 (n = 1413) 61 (59–64) 34 (31–36) 26 (24–29) ref 
Middle 67–72 (n = 1590) 65 (62–67) 36 (34–39) 28 (26–30) 0.097 
High 73–95 (n = 1793) 67 (65–69) 41 (38–43) 32 (30–34) <0.0001  
2015− 2017 
Low 54–66 (n = 1557) 63 (61− 66) 35 (33–37)  ref 
Middle 67–74 (n = 1833) 65 (63− 67) 38 (36–40)  0.094 
High 75–89 (n = 1929) 70 (68− 72) 41 (38–43)  <0.0001  
Gastric cancer 
Probability of undergoing treatment with curative intent in % 1 yr RS in % (95 % CI) 3 yr RS in % (95 % CI) 5 yr RS in % (95 % CI) P 
52–68 (n = 782) 56 (52–59) 32 (29–36) 25 (22–28) ref 
69 – 80(n = 664) 60 (56–64) 34 (30–38) 26 (23–30) 0.315 
81 – 100 (n = 772) 63 (60–67) 39 (36–42) 32 (28–35) <0.0001  
45 – 68 (n = 594) 57 (53–61) 34 (30–38)  ref 
69 – 74 (n = 483) 60 (56–64) 36 (31–40)  0.648 
75 – 100 (n = 690) 64 (60–67) 39 (36–43)  0.037 
Patients were divided in 3 groups with a similar number of hospitals according to the adjusted probability to undergo curative treatment of the hospital in which they 
were diagnosed. P value was calculated using a two sample proportion test. 
Esophageal cancer (EC) gastric cancer (GC) Relative survival (RS). 
Table 4 
Relative Excess Risks of death for esophageal and gastric cancer.   
Esophageal cancer Gastric cancer  
Probability of undergoing treatment with curative intent RER 95 %CI p-value RER 95 %CI p- value 
2012− 2014 Low probability 1.00    1.00     
Middle probability 0.93 0.86 1.01 0.097 0.94 0.83 1.06 0.315  
High probability 0.84 0.77 0.91 <0.0001 0.81 0.72 0.91 <0.0001  
2015− 2017 Low probability 1.00    1.00     
Middle probability 0.94 0.86 1.02 0.119 0.97 0.83 1.12 0.648  
High probability 0.84 0.77 0.91 <0.0001 0.86 0.75 0.99 0.037 
Relative Excess Risks of death (RER). 
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found in the period in which centralization of surgery was initiated and 
did not remain in later time periods [3]. A study in patients diagnosed 
with ovarian cancer found that variation between hospitals decreased 
due to centralization of surgical care [31]. Since centralization of gas-
trectomies was initiated later than centralization for esophagectomies, 
this could at least partly explain the unchanged variation in GC. Other 
potential explanations for differences in variation between EC and GC 
might be more treatment options for EC (e.g. definitive chemoradiation 
and more palliative options) as opposed to surgery (with or without 
perioperative treatment) and less palliative options in GC. More 
importantly, since 2016, the Dutch guidelines included PET and staging 
laparoscopy in the staging algorithm of locally advanced (cT3–4) gastric 
tumors, which could affect the proportion of patients being potentially 
curable and receiving curative treatment [23]. 
Strengths of this study include the population-based design. More-
over, we were able to correct for ECOG and comorbidities in a subset of 
patients in the multivariable analyses. Since ECOG and comorbidities 
play an essential role in treatment decision-making and are not regis-
tered for the complete time period in the NCR, this can also be seen as a 
limitation. Especially since findings regarding the influence of ECOG 
and comorbidities may have differed for early pre-centralization years. 
Other limitations of this study are that the initial intention of the chosen 
therapy was not registered but assumed. As only potentially curable EC 
or GC patients were included in this study, it was assumed that they 
received neoadjuvant chemo(radiation) or underwent definitive che-
moradiation with curative intent. However, this could lead to a potential 
overestimation of the number of patients that underwent treatment with 
curative intent. One could argue that the larger proportion of missing T 
stages in 2012− 2014, (42 % GC) when compared with 2015− 2017 (30 
%), might be due to a more frequent use of diagnostic application of 
endoscopic ultrasound which could explain the observed variation. 
However, treatment choices in this patient group depend more on N and 
M stage, than on the T stage, apart from the T4b-status, which was not 
included in this study. Additionally, since MDTMs facilitate adherence 
to clinical practice guidelines, [40,41] it would have been interesting to 
investigate the effect of discussing cases in a low versus high volume or 
local versus regional MDTM. Nevertheless, this data was not registered 
in the NCR for the whole study period and thus further research is 
needed in order to assess the impact of discussing patients in a tumor 
specific Upper-GI MDTM incorporating expert centers and assess the 
effect of the implementation of regional clinical pathways. 
In conclusion, our study has shown that in 2012–2017 period, vari-
ation in probability of undergoing treatment with curative intent be-
tween the different hospitals of diagnosis in the Netherlands decreased 
for EC but remained stable for GC. Survival was better for patients 
diagnosed in a hospital in which the probability of undergoing treatment 
with curative intent was high. Decisive factors associated with the 
variability are still unclear. Further research is needed to elucidate these 
factors explaining variation, which may improve care for patients 
diagnosed with these malignancies. 
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Appendix A. Treatment with curative intent in hospital of diagnosis <10 versus >10  
Esophageal cancer Gastric cancer 
Year of diagnosis <10 >10 Year of diagnosis <10 >10 
2012− 2014 0.06% (n = 3) 99 % (n = 4795) 2012− 2014 2% (n = 52) 98 % (n = 2218) 
2015− 2017 0.1% (n = 6) 99.9 %(n = 5319) 2015− 2017 4% (n = 72) 96 %(n = 1770)  
N = 9 N = 10,114  N = 124 N = 3988  
Appendix B. Distribution of all potentially curable and palliative esophageal and gastric cancer according to year of diagnosis  
Esophageal cancer  Gastric cancer  
Year of diagnosis Potentially curable Palliative Total P value Year of diagnosis Potentially curable Palliative Total P value 
2012 1610 (63 %) 937 (37 %) 2564 0.60 2012 777 (59 %) 538 (41 %) 1315 <0.01 
2013 1597 (63 %) 942 (37 %) 2567  2013 759 (60 %) 504 (40 %) 1263  
2014 1592 (61 %) 1009 (39 %) 2633  2014 734 (61 %) 468 (39 %) 1202  
2015 1737 (62 %) 1057 (38 %) 2841  2015 616 (55 %) 500 (45 %) 1116  
2016 1796 (62 %) 1087 (38 %) 2937  2016 682 (55 %) 491 (45 %) 1173  
2017 1792 (63 %) 1033 (37 %) 2873  2017 544 (53 %) 471 (47 %) 1015  
Total 10,124 6291 16,415  Total 4112 2968 7080   
Treatment with curative intent in hospital of diagnosis <10 were excluded from analyses. 
Appendix C. Changes in probability of curative treatment between 2012¡2014 and 2015¡2017 per hospital   
Number of hospitals EC Number of hospitals GC 
No change in probability of curative treatment 34 (46 %) 28 (47 %) 
Low – low probability 11 (15 %) 10 (17 %) 
Medium – medium probability 9 (12 %) 6 (10 %) 
High – high probability 14 (19 %) 12 (20 %) 
Decrease in probability of curative treatment 21 (29 %) 17 (28 %) 
Medium – low probability 11 (15 %) 6 (10 %) 
High – low probability 3 (4%) 5 (8%) 
High – medium probability 7 (9.6 %) 6 (10 %) 
Increase in probability of curative treatment 18 (25 %) 15 (25 %) 
Low – medium probability 7 (9.6 %) 8 (13 %) 
Low – High probability 5 (6.9 %) 6 (10 %) 
Medium – high probability 6 (8%) 1 (2%)  
Esophageal cancer (EC) gastric cancer (GC), 
Due to fusions of hospitals and bankruptcies not all hospitals are represented in both periods, therefore numbers might not add up. 
Appendix D. 3-year relative survival in all patients, potentially curable patients and 1 year relative survival in palliative patients in the 
period 2012¡2014 and 2015¡2017 in the Netherlands   
Esophageal cancer Gastric cancer  
2012− 2014 RS 
in % (95 % CI) 
Number of 
patients 
2015− 2017 RS 





2012− 2014 RS 
in % (95 % CI) 
Number of 
patients 
2015− 2017 RS 





3-year RS All 
patients 




38 % (37− 40) 4845 40 % (38− 41) 5461 0.117 36 % (34− 38) 2279 38 % (35− 40) 1859 0.299 
1-year RS 
Palliative 
21 % (20− 23) 2919 22% (21− 24) 3202 0.248 18% (17− 20) 1516 17 % (15− 19) 1470 0.81  
P value was calculated using a two sample proportion test. 
Relative survival (RS). 
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